home
investors
newsroom
licensing
careers
contact us
United States
Canada
MSD Worldwide
About Us
Our Values
Be well
Leadership
How We Operate
Views and Positions
Our History
Featured Stories
Corporate Responsibility
Research
Pipeline
Discovery & Development
Products
Vaccines
Prescription Products & Prescribing Information
Consumer Products
Animal Health
INVESTED IN
YOUR FUTURE
Financials
Annual Reports, Proxy Statements, and Form 10-K
SEC Filings & Certifications
Earnings Releases
Quarterly Financials
Stock Information
Stock Chart
Historical Price Lookup
Stock Splits
Cash Dividend History
Investment Calculator
Partnerships
Events & Presentations
Stockholder Services
Information Request
Forward-Looking Statement
Contact Us
LATEST NEWS
more news
Feb. 02, 2012
FDA Approves JANUMET
®
XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET
®
(sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
Feb. 02, 2012
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
Jan. 26, 2012
Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2
Print
Share
Text Size
Access
Related Information
2010 Merck Annual Report (Animal Health updated 3/22/11)
Corporate Responsibility Report
Product Pipeline
Learn more
Vaccine Supply
Merck Vaccine Supply Status Update
Podcast